USA Proton Therapy Market to exceed USD 15 Billion by 2021, with CAGR of 6.04 Percent
25 Apr, 2017

A new report by Renub Research, titled “United States Proton Therapy Market & Forecast, Reimbursement Policy and Patients Treated at Proton Therapy Centers” provides comprehensive insight of United States Proton Therapy Market. Proton therapy evolves as a prime radiation treatment modality. The compliance of proton therapy into clinical practice for more than 2 decades in United States makes it one of the advanced radio therapy tool to fight deadly cancerous tumor like Brain cancer, Eye cancer, Prostate cancer, Colon and rectal cancer, Breast cancer etc. In recent times, many research institutes and hospitals are investing in proton therapy to make proton therapy technology more affordable and accessible to patients. Rising cancer prevalence and increasing waiting list of high risk cancer patients shows high credential and acceptance of proton therapy in United States.

Proton Therapy Market in United States

The potential demand of proton therapy market in United States for the year 2021 is expected to be higher than USD 15 Billion, growing with a CAGR of 6.04 percent. USA holds the major market share in Global Proton Therapy Market.

Proton Therapy is far better than Standard Therapy

There was paradigm shift in terms of utilization of radiotherapy over the several decades and photons come into existence with absence of randomized clinical trials. The adoption of photons (radiotherapy) continues to strive to limit the dose to normal tissues. The core reason for this is the unable to control the exit dose downstream from the target (tumor), which is a physical limitation of the megavoltage photon beam. Then, proton beam therapy (PBT) is come under attention. Contrasting photons, protons deposit almost all of their energy at a defined and controllable depth from the skin surface, specifically avoiding the exit dose. Therefore it mitigates the risk of damage to nearby healthy tissue and vanish negative side effects.

Proton Therapy provides Treatment Possibility for Recurrent Lung Cancer in United States

According to recent study by Multidisciplinary Thoracic Cancers Symposium, the major death of cancer patients in United States caused by lung cancer than any other type of cancer, because of its Invasive form and likelihood of recurrence. In historical facts, recurrences have been exception to treat; due to majority of these patients are not opt for surgery. The most patients with reoccurrence lung cancer offered palliative options as a last resort to manage pain. Proton therapy, permit radiation oncologists to recognize normal tissues and spare them while delivering escalated, curative doses of radiation to nearby tumors. Moreover, IMPT has ability to exactly target a tumor.

About Us

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us

Renub Research

Phone: +1-678-302-0700

Email: info@renub.com

Website: http://www.renub.com     

Follow us on LinkedIn: http://www.linkedin.com/company/renub-research